Anne Prener is a Venture Partner at SV and CEO of Imbria, an SV portfolio company. She joined the SV Venture Partner Program in September 2020 and was the first CEO of Cellinta, another SV portfolio company.
Anne has more than 25 years of experience in leading biotechnology companies and teams across several therapeutic areas with a special focus on rare diseases and gene therapy. She currently serves as a Board Director for Rubius Therapeutics, Kaleido Bioscience and Renovacor. Prior to joining SV and Cellinta, Anne served as President and CEO of Freeline Ltd., a liver-directed gene therapy company, where she scaled the company from preclinical stage to a fully integrated biotechnology organization, which included a broad, internally developed pipeline, two programs in clinical development and a commercial- scale, high-quality CMC and manufacturing platform.
Prior to joining Freeline, Anne served as CEO of Gyroscope Therapeutics Ltd., a gene therapy company focused on eye diseases. Before that, Anne was Vice President, clinical research hematology and Global Therapeutic Area Head of hematology at Baxalta. During her time there, three new major product approvals in both the U.S. and EU were secured along with a significant advancement in Baxalta’s hematology portfolio, including gene therapy for hemophilia. Earlier in her career, Anne held several positions of increasing responsibility at Novo Nordisk, most recently serving as Senior Vice President, Hemophilia R&D portfolio where she was instrumental in building the hemophilia franchise to a portfolio of several late stage and commercial products.
M.D and Ph.D. in epidemiology both from the University of Copenhagen, Denmark.